Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Neuroprotective drugs tested in clinical trials, particularly those that block N-methyl-D-aspartate-sensitive glutamate receptors (NMDARs), have failed miserably in large part because of intolerable side effects. However, one such drug, memantine, was recently approved by the European Union and the US FDA for the treatment of dementia following our group's discovery of its clinically tolerated mechanism of action. Here, we review the molecular basis for memantine efficacy in neurological diseases that are mediated, at least in part, by overactivation of NMDARs, producing excessive Ca(2+) influx through the receptor's associated ion channel and consequent free-radical formation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The discrepancy in ketamine IC50 values between these two studies might be explained by the concentration of agonist used (50 μM versus 1 mM glutamate), as higher agonist concentrations allow non-competitive antagonists, e.g. ketamine, to block more effectively due to a greater number of open channels”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Lipton, 2006
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972 · cited 1×
“D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK293 and N1E-115 cell systems in a non-competitive manner.”
BackgroundAlzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Magnesium gates glutamate-activated channels in mouse central neurones
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., & Prochiantz, A. (1984) · Nature · doi:10.1038/307462a0 · Cited by 4,043
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139 · cited 1×
“The NR2 family of NMDAR subunits contains a binding site for glutamate, the endogenous agonist, whereas the NR1 subunit binds glycin”
BackgroundVoltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones
Mayer, M. L., Westbrook, G. L., & Guthrie, P. B. (1984) · Nature · doi:10.1038/309261a0 · Cited by 2,893
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658 · cited 1×
“kon Channel + MEM ↔ Channel–MEM (Blocked channel) (1)”
Self-citationMolecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543
Heteromeric NMDA receptors: molecular and functional distinction of subtypes
Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., & Seeburg, P. H. (1992) · Science · doi:10.1126/science.256.5060.1217 · Cited by 2,541
Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Self-citationNitric oxide mediates glutamate neurotoxicity in primary cortical cultures.
Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., & Snyder, S. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.6368 · Cited by 2,174
Research works printed but not linked: 5
- Chen, H. -S. V. & Lipton, S. A. in Post Genomic Drug Discovery Research (ed. Huang, Z.) (John Wiley & Sons, Hoboken, NJ (in the press).
- Navia, B. A., Yiannoutsos, C., Ellis, R., Schifitto, G., Nath, A., Shriver, S., Millar, L. & Lipton, S. A. Memantine may prevent further cognitive decline in subjects with AIDS Dementia Complex with detectable CSF HIV RNA. Neurology 64 (Suppl. 1), A247–A238 (2005).
- Lipton, S. A., Rayudu, P. V., Choi, Y. -B., Sucher, N. J. & Chen, H. -S. V. in Prog Brain Res. (eds Mize, V., Dawson, T. M., Dawson, M. & Friedlander, M.) 73–82 (Elsevier, Amsterdam, 1998).
- Káradóttir, R., Cavelier, P., Bergersen, L. H. & Atwell, D. NMDA receptors in oligodendrocyte physiology and pathology. Nature (in the press).
- Micu, I. et al. NMDA receptors mediate Ca accumulation in central nervous system myelin during chemical ischemia. Nature (in the press).
Cited by
The Science of Stroke: Mechanisms in Search of Treatments
Moskowitz, M. A., Lo, E. H., & Iadecola, C. (2010) · Neuron · doi:10.1016/j.neuron.2010.07.002 · Cited by 1,930
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Oxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease
Tönnies, E., & Trushina, E. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161088 · Cited by 1,750
“Importantly, memantine has greater affinity to non-synaptic NMDA receptors, which are implicated in excitotoxicity associated with the glutamate spillover and have distinctly different composition of receptor subunits [164, 165].”
BackgroundFunctional Repression of cAMP Response Element in 6-Hydroxydopamine-treated Neuronal Cells
Chalovich, E. M., Zhu, J.-H., Caltagarone, J., Bowser, R., & Chu, C. T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602632200 · Cited by 1,371
Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188
“Because the Alzheimer’s drug Namenda (memantine) is thought to function therapeutically as an openchannel blocker of NMDA receptors (Lipton, 2006) and NMDA receptors codistribute in hippocampal cultures with ADDLs, we tested whether memantine might exhibit efficacy in blocking ADDL-induced drebrin…”
BackgroundX-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor
Sobolevsky, A. I., Rosconi, M. P., & Gouaux, E. (2009) · Nature · doi:10.1038/nature08624 · Cited by 1,026
Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease
Bezprozvanny, I., & Mattson, M. P. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.005 · Cited by 938
The Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization
Hamley, I. W. (2012) · Chemical Reviews · doi:10.1021/cr3000994 · Cited by 882
De Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882
Parsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 707
“Rogawski and Wenk, 2003; Lipton, 2006; Wenk et al., 2006; Bullock, 2006).”
BackgroundThe Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives
Wanka, L., Iqbal, K., & Schreiner, P. R. (2013) · Chemical Reviews · doi:10.1021/cr100264t · Cited by 696
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Neuroinflammation in Alzheimer disease
Heneka, M. T., van der Flier, W. M., Jessen, F., Hoozemanns, J., Thal, D. R., Boche, D., Brosseron, F., Teunissen, C., Zetterberg, H., Jacobs, A. H., et al. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01104-7 · Cited by 638
“These data confirm an NMDA receptor–nNOS-dependent route contributing to AD pathology, consistent with earlier studies and clinical trials, where application of the NMDA receptor antagonist memantine (an open-channel blocker) reduced excitotoxicity and ameliorated AD pathology 515 .”
Amyloid beta oligomers induce impairment of neuronal insulin receptors
Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587
“Protection against ADDLs afforded by memantine may likely be relevant to the therapeutic effect of this drug in AD patients (51, 71, 75).”
BackgroundThe Role of NMDA Receptors in Alzheimer’s Disease
Liu, J., Chang, L., Song, Y., Li, H., & Wu, Y. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00043 · Cited by 535
“To date, memantine is the only NMDAR antagonist that is clinically approved and preferentially acts as an antagonist of non-synaptic NMDARs (Lipton, 2006).”
BackgroundDAPK1 Interaction with NMDA Receptor NR2B Subunits Mediates Brain Damage in Stroke
Tu, W., Xu, X., Peng, L., Zhong, X., Zhang, W., Soundarapandian, M. M., Belal, C., Wang, M., Jia, N., Zhang, W., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.055 · Cited by 493
“Ca 2+ overload triggers multiple intracellular catabolic processes, and thus induces an irreversible death of neuronal cells in the brain (for review, see Lipton, 2006; Lo et al., 2003).”
InfluentialCalcium signaling and neurodegenerative diseases
Bezprozvanny, I. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.001 · Cited by 469
The chemical biology of clinically tolerated NMDA receptor antagonists
Chen, H. V., & Lipton, S. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03991.x · Cited by 474
Self-citationOkamoto, S.-I., Pouladi, M. A., Talantova, M., Yao, D., Xia, P., Ehrnhoefer, D. E., Zaidi, R., Clemente, A., Kaul, M., Graham, R. K., et al. (2009) · Nature Medicine · doi:10.1038/nm.2056 · Cited by 436
“We have shown that, unlike other NMDAR antagonists, such as ifenprodil and D -APV, memantine is an open-channel blocker, acting predominantly via a mechanism characterized by u ncompetitive inhibition with a f ast ' o ff-rate' (designated UFO drug action); through this mechanism low micromolar concentrations of the dr…”
BackgroundSelf-citationProlonged and tunable residence time using reversible covalent kinase inhibitors
Bradshaw, J. M., McFarland, J. M., Paavilainen, V. O., Bisconte, A., Tam, D., Phan, V. T., Romanov, S., Finkle, D., Shu, J., Patel, V., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1817 · Cited by 422
Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95
Zhou, L., Li, F., Xu, H.-B., Luo, C.-X., Wu, H.-Y., Zhu, M.-M., Lu, W., Ji, X., Zhou, Q.-G., & Zhu, D.-Y. (2010) · Nature Medicine · doi:10.1038/nm.2245 · Cited by 414
Indian Journal of Public Health Research & Development
Surwade, V. M., Ambedkar, B. S., Rohinee, & Delhi (2019) · Cited by 401
Xia, P., Chen, H.-S. V., Zhang, D., & Lipton, S. A. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2488-10.2010 · Cited by 379
“The fact that low micromolar memantine displays a preference for blocking extrasynaptic over synaptic NMDARs may help explain why memantine manifests a therapeutic effect with few side effects in its clinical use in humans (Lipton, 2006, 2007; Okamoto et al., 2009).”
BackgroundMethodSelf-citationStrategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors
Johnson, D. S., Weerapana, E., & Cravatt, B. F. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.21 · Cited by 387
“However, covalent binding may not be optimal for targets when the mechanism of action requires short residence time, transient inhibition or partial inhibition [49,50].”
BackgroundNuclear calcium signalling in the regulation of brain function
Bading, H. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3531 · Cited by 373
Calcium signaling and molecular mechanisms underlying neurodegenerative diseases
Pchitskaya, E., Popugaeva, E., & Bezprozvanny, I. (2018) · Cell Calcium · doi:10.1016/j.ceca.2017.06.008 · Cited by 349
“An exception is a non-competitive NMDAR inhibitor memantine, which is currently approved for AD treatment (Lipton, 2006).”
BackgroundRaymond, L. A., André, V. M., Cepeda, C., Gladding, C. M., Milnerwood, A. J., & Levine, M. S. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.052 · Cited by 325
“Model of mutant htt induced synaptic dysfunction in HD. Aberrant glutamate release from cortical and thalamic afferents stimulates postsynaptic and Ex-NMDARs on MSNs. Overactivation of Ex-NMDARs also may be facilitated by deficits in glutamate uptake by the transporter GLT-1 on astrocytes.”
BackgroundInfluentialSharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
Jacob, C. P., Koutsilieri, E., Bartl, J., Neuen-Jacob, E., Arzberger, T., Zander, N., Ravid, R., Roggendorf, W., Riederer, P., & Grünblatt, E. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-11113 · Cited by 317
“As a consequence of Ca 2+ accumulation, excessive activation of the NMDARs leads to production of damaging free radicals and other enzymatic processes contributing to cell death [22].”
d‐Amino acids in the brain:d‐serine in neurotransmission and neurodegeneration
Wolosker, H., Dumin, E., Balan, L., & Foltyn, V. N. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06515.x · Cited by 309
Glutamate receptors at atomic resolution
Mayer, M. L. (2006) · Nature · doi:10.1038/nature04709 · Cited by 290
“Impetus for this is a growing body of evidence that glutamate receptors have key roles in a much broader variety of neurodegenerative and psychiatric diseases than first anticipated and the approval of the NMDA-receptor channel blocker Memantine for treatment of dementia in the United States and the European Unio”
BackgroundLéveillé, F., gaamouch, F. E., Gouix, E., Lecocq, M., Lobner, D., Nicole, O., & Buisson, A. (2008) · The FASEB Journal · doi:10.1096/fj.08-107268 · Cited by 257
Mechanism of NMDA receptor channel block by MK-801 and memantine
Song, X., Jensen, M. Ø., Jogini, V., Stein, R. A., Lee, C.-H., Mchaourab, H. S., Shaw, D. E., & Gouaux, E. (2018) · Nature · doi:10.1038/s41586-018-0039-9 · Cited by 264
Qiu, J., Tan, Y.-W., Hagenston, A. M., Martel, M.-A., Kneisel, N., Skehel, P. A., Wyllie, D. J. A., Bading, H., & Hardingham, G. E. (2013) · Nature Communications · doi:10.1038/ncomms3034 · Cited by 266
Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs
Satoh, T., McKercher, S. R., & Lipton, S. A. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.07.022 · Cited by 267
Self-citationMg2+Imparts NMDA Receptor Subtype Selectivity to the Alzheimer's Drug Memantine
Kotermanski, S. E., & Johnson, J. W. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3703-08.2009 · Cited by 271
“NMDAR responses were activated with a saturating [glutamate] (1 mM) and [glycine] (100 M) to avoid possible agonist concentration dependence of memantine inhibition (Lipton, 2006) (but see Parsons et al.”
BackgroundMethodResultInfluentialPathologically activated therapeutics for neuroprotection
Lipton, S. A. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2229 · Cited by 257
“These include cognitive problems, hallucinations and even com”
BackgroundSelf-citationCoupling of the NMDA receptor to neuroprotective and neurodestructive events
Hardingham, G. E. (2009) · Biochemical Society Transactions · doi:10.1042/bst0371147 · Cited by 261
“Chronic neurodegenerative diseases may also be associated with excessive NMDAR activation [81, 82].”
BackgroundPharmaceuticals that contain polycyclic hydrocarbon scaffolds
Stockdale, T. P., & Williams, C. M. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00477a · Cited by 250
Memantine for the Treatment of Dementia: A Review on its Current and Future Applications
Folch, J., Busquets, O., Ettcheto, M., Sánchez-López, E., Castro-Torres, R. D., Verdaguer, E., Garcia, M. L., Olloquequi, J., Casadesús, G., Beas-Zarate, C., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170672 · Cited by 245
“presenting MEM as a potential treatment for various neurological diseases [14, 15].”
BackgroundMolecular Mechanisms of Glutamate Toxicity in Parkinson’s Disease
Wang, J., Wang, F., Mai, D., & Qu, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.585584 · Cited by 227
“However, most NMDAR antagonists are competitive antagonists that can affect the physiological function of the brain and have negative side effects (Lipton, 2006).”
BackgroundA review on advances of treatment modalities for Alzheimer's disease
Se Thoe, E., Fauzi, A., Tang, Y. Q., Chamyuang, S., & Chia, A. Y. Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119129 · Cited by 219
Cell Signaling and Neuronal Death
Hara, M. R., & Snyder, S. H. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105311 · Cited by 224
Nakamura, T., & Lipton, S. A. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.65 · Cited by 222
“These new drugs, called NitroMemantines, use memantine to target the NO group to the nitrosylation sites of the NMDAR.3,92 Because memantine, as an uncompetitive antagonist preferentially enters overactive NMDAR-coupled channels, it serves to bring NO directly to the NMDAR where it helps to curtail excessive activity,…”
BackgroundInfluentialSelf-citationImmunomodulatory and therapeutic activity of curcumin
Srivastava, R. M., Singh, S., Dubey, S. K., Misra, K., & Khar, A. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2010.08.014 · Cited by 215
Neurological implications of urea cycle disorders
Gropman, A. L., Summar, M., & Leonard, J. V. (2007) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-007-0709-5 · Cited by 218
“Memantine works by open-channel blockade, which requires prior activation of the receptor, and is a unique mechanism among NMDA-receptor antagonists (Lipton 2006).”
BackgroundBordji, K., Becerril-Ortega, J., Nicole, O., & Buisson, A. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3021-10.2010 · Cited by 197
“This is in accordance with previous observations reporting that memantine only acts under pathological conditions without much affecting normal functions, and so relatively spares normal excitatory synaptic function (Lipton, 2006 and 2007).”
ResultCombination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use
Taylor, C. P., Traynelis, S. F., Siffert, J., Pope, L. E., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.010 · Cited by 186
Cell death: protein misfolding and neurodegenerative diseases
Nakamura, T., & Lipton, S. A. (2009) · Apoptosis · doi:10.1007/s10495-008-0301-y · Cited by 189
“, NO reaction with the sulfhydryl group of a critical cysteine residue, down-regulates (but does not completely shut off) receptor activity [11, 21].”
InfluentialSelf-citationInfluence of the NR3A subunit on NMDA receptor functions
Henson, M. A., Roberts, A. C., Pérez-Otaño, I., & Philpot, B. D. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.01.004 · Cited by 170
Pharmacodynamics of Memantine: An Update
Parsons, C., Rammes, G., & Danysz, W. (2008) · Current Neuropharmacology · doi:10.2174/157015908783769671 · Cited by 183
“Based on this knowledge, it seems reasonable to investigate whether ligands specific for either receptor, might have affinity for both.”
BackgroundCalcium Dyshomeostasis in Alzheimer’s Disease Pathogenesis
Cascella, R., & Cecchi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094914 · Cited by 185
New Approaches for the Treatment of Alzheimer’s Disease
Fish, P. V., Steadman, D., Bayle, E. D., & Whiting, P. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.11.034 · Cited by 189
Rosini, M., Simoni, E., Bartolini, M., Cavalli, A., Ceccarini, L., Pascu, N., McClymont, D. W., Tarozzi, A., Bolognesi, M. L., Minarini, A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800577j · Cited by 185
S-Nitrosylation activates Cdk5 and contributes to synaptic spine loss induced by β-amyloid peptide
Qu, J., Nakamura, T., Cao, G., Holland, E. A., McKercher, S. R., & Lipton, S. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105172108 · Cited by 185
Self-citationTarget–drug interactions: first principles and their application to drug discovery
Núñez, S., Venhorst, J., & Kruse, C. G. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.013 · Cited by 181
The Subtype of GluN2 C-terminal Domain Determines the Response to Excitotoxic Insults
Martel, M.-A., Ryan, T. J., Bell, K. F. S., Fowler, J. H., McMahon, A., Al-Mubarak, B., Komiyama, N. H., Horsburgh, K., Kind, P. C., Grant, S. G. N., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.021 · Cited by 176
“A major cause of glutamate excitotoxicity is inappropriate activity of the NMDA subtype of glutamate receptor (NMDAR), which mediates Ca2+-dependent cell death (Choi, 1992; Lipton, 2006).”
Physiological Roles of Non-Neuronal NMDA Receptors
Hogan-Cann, A. D., & Anderson, C. M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.012 · Cited by 173
The Dichotomy of NMDA Receptor Signaling
Papadia, S., & Hardingham, G. E. (2007) · The Neuroscientist · doi:10.1177/10738584070130060401 · Cited by 176
“Chronic neurodegenerative diseases may also be associated with excessive NMDAR activation (Lipton 2006; Lipton and Rosenberg 1994).”
BackgroundChoo, A. M., Liu, J., Lam, C. K., Dvorak, M., Tetzlaff, W., & Oxland, T. R. (2007) · Journal of Neurosurgery: Spine · doi:10.3171/spi.2007.6.3.255 · Cited by 169
The Mu-Opioid Receptor and the NMDA Receptor Associate in PAG Neurons: Implications in Pain Control
Rodríguez-Muñoz, M., Sánchez-Blázquez, P., Vicente-Sánchez, A., Berrocoso, E., & Garzón, J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.155 · Cited by 170
“These include neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis (Lipton, 2006), and mood disorders, such as schizophrenia and depression (Mechri et al, 2001; Maeng and Zarate, 2007).”
BackgroundYu, S. P., Jiang, M. Q., Shim, S. S., Pourkhodadad, S., & Wei, L. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00636-1 · Cited by 189
“Most of these compounds were MEM derivatives, such as MN-08 (a MEM nitrate) [153, 268, 318], fluoroethylnormemantine (FENM) [319, 320], and NitroSynapsin [153].”
BackgroundMethodMechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Beard, R. S., Reynolds, J. J., & Bearden, S. E. (2011) · Blood · doi:10.1182/blood-2011-02-338269 · Cited by 167
Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity
Volbracht, C., Van Beek, J., Zhu, C., Blomgren, K., & Leist, M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04787.x · Cited by 174
“memantine, like Mg, leaves the NMDA-R channel due to its voltage-dependency and fast unblocking kinetics (reviewed in Kornhuber & Weller, 1997; Lipton, 2006).”
BackgroundInfluentialWu, H.-M., Tzeng, N.-S., Qian, L., Wei, S.-J., Hu, X., Chen, S.-H., Rawls, S. M., Flood, P., Hong, J.-S., & Lu, R.-B. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.64 · Cited by 174
“…after LPS Treatment in Primary Midbrain Neuron-Glia Cultures Since memantine is a NMDA receptor blocker, most of the reports attributed neuroprotective effects or clinical therapeutic benefits of this compound to its inhibitory effects on NMDA-receptor mediated excitotoxicity (Lipton, 2006).”
BackgroundCurrent Approaches to the Treatment of Post-Stroke Aphasia
Fridriksson, J., & Hillis, A. E. (2021) · Journal of Stroke · doi:10.5853/jos.2020.05015 · Cited by 172
Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease
Paula‐Lima, A. C., Brito‐Moreira, J., & Ferreira, S. T. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12304 · Cited by 170
Cognition enhancers between treating and doping the mind
Lanni, C., Lenzken, S. C., Pascale, A., Del Vecchio, I., Racchi, M., Pistoia, F., & Govoni, S. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.02.004 · Cited by 166
“Memantine: Memantine [25] has been used for almost 25 ears in Germany for the cognitive impairment of the elderly nd more recently registered for severe Alzheimer’s disease.”
MethodSchifitto, G., Navia, B. A., Yiannoutsos, C. T., Marra, C. M., Chang, L., Ernst, T., Jarvik, J. G., Miller, E. N., Singer, E. J., Ellis, R. J., et al. (2007) · AIDS · doi:10.1097/qad.0b013e32813384e8 · Cited by 166
“Its better toxicity profile when compared to other NMDA receptor antagonists such as eliprodil and CNS 1102 likely reflects its ability to effectively block neurotoxic levels of glutamate agonists with relative sparing of neurotransmission [17].”
BackgroundSelf-citationGLT-1 Loss Accelerates Cognitive Deficit Onset in an Alzheimer's Disease Animal Model
Mookherjee, P., Green, P. S., Watson, G. S., Marques, M. A., Tanaka, K., Meeker, K. D., Meabon, J. S., Li, N., Zhu, P., Olson, V. G., et al. (2011) · Journal of Alzheimer’s Disease · doi:10.3233/jad-2011-110503 · Cited by 163
“…NMDA receptors, has efficacy in treating the hypothesis that aberrant glutamatergic activity may underlie pathogenic aspects of the disease process [11] number of studies have found that GLT-1 is Considering the critical neuroprotective functions carried out by GLT-1, such findings raise the…”
The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Blasco, H., Mavel, S., Corcia, P., & Gordon, P. H. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140916120118 · Cited by 164
“The principle effect of memantine on reducing neuronal loss occurs through correction of excitation-inhibition imbalance [290, 291, 295, 304, 305] at the level of the NMDA receptor [290, 291, 304, 305], but the compound has numerous targets.”
BackgroundNeuronal Calcium Signaling, Mitochondrial Dysfunction, and Alzheimer's Disease
Supnet, C., & Bezprozvanny, I. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100306 · Cited by 160
“Potentially more specific NMDAR inhibitors such as nitromemantines can be developed [107].”
Protein S -Nitrosylation as a Therapeutic Target for Neurodegenerative Diseases
Nakamura, T., & Lipton, S. A. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.10.002 · Cited by 160
“Accordingly, unlike other NMDAR antagonists that persistently block channel activity and cause severe side effects, memantine spares synaptic function under physiological conditions [79,80].”
Self-citationSupramolecular Hydrogels Fabricated from Supramonomers: A Novel Wound Dressing Material
Xu, W., Song, Q., Xu, J.-F., Serpe, M. J., & Zhang, X. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b02850 · Cited by 166
Simoni, E., Daniele, S., Bottegoni, G., Pizzirani, D., Trincavelli, M. L., Goldoni, L., Tarozzo, G., Reggiani, A., Martini, C., Piomelli, D., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3009458 · Cited by 163
Bukke, V. N., Archana, M., Villani, R., Romano, A. D., Wawrzyniak, A., Balawender, K., Orkisz, S., Beggiato, S., Serviddio, G., & Cassano, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207452 · Cited by 161
“The non-competitive NMDA receptor antagonist memantine has an inhibitory effect on NMDA receptor-mediated excitotoxicity, improves cognition, slowdowns disease progression and reduces tau phosphorylation [32,33,211,226].”
BackgroundBading, H. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20161673 · Cited by 157
“…animal models of neurodegeneration, which include AD, HD, ALS, and the experimental autoimmune encephalomyelitis model 573JEM Vol. 214, No. 3 of MS (Parsons et al., 1999; Wang and Zhang, 2005; Lipton, 2006; Okamoto et al., 2009; Milnerwood et al., 2010; Talantova et al., 2013; Sühs et al., 2014).”
BackgroundNieoullon, A., Canolle, B., Masmejean, F., Guillet, B., Pisano, P., & Lortet, S. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03978.x · Cited by 156
Age‐ and disease‐specific changes of the kynurenine pathway in Parkinson’s and Alzheimer’s disease
Sorgdrager, F. J. H., Vermeiren, Y., van Faassen, M. H. J. R., van der Ley, C., Nollen, E. A. A., Kema, I. P., & Deyn, P. P. D. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14843 · Cited by 175
Neuroprotection in glaucoma – Is there a future role?
Baltmr, A., Duggan, J., Nizari, S., Salt, T. E., & Cordeiro, M. F. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.08.009 · Cited by 177
“The additional amine (eNH2) and twomethyl (eCH3) side groups are thought to be responsible for the increased residencywith and affinity forNMDA receptors in relation to amantadine (Lipton, 2006).”
BackgroundCoupling of NMDA receptors and TRPM4 guides discovery of unconventional neuroprotectants
Yan, J., Bengtson, C. P., Buchthal, B., Hagenston, A. M., & Bading, H. (2020) · Science · doi:10.1126/science.aay3302 · Cited by 159
Glutamate Transporter EAAT2: A New Target For The Treatment Of Neurodegenerative Diseases
Lin, C. G., Kong, Q., Cuny, G. D., & Glicksman, M. A. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.122 · Cited by 169
“USA 89(22), 10955–10959 (1992).”
Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease
Unzeta, M., Esteban, G., Bolea, I., Fogel, W. A., Ramsay, R. R., Youdim, M. B. H., Tipton, K. F., & Marco-Contelles, J. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00205 · Cited by 144
“Althoughmemantine was initially regarded as a poor drug candidate for AD therapy, the mechanisms by which exerts clinical benefits and its safe profile have attracted a great considerable interest in the field of medicinal chemistry (Lipton, 2006).”
BackgroundIkram, M. A., Park, T. J., Ali, T., & Kim, M. O. (2020) · Antioxidants · doi:10.3390/antiox9090902 · Cited by 170
“Apart from the reactive species, the reactive nitrogen species (RNS), including nitric oxide (NO), also contribute to neuronal cell death and neurodegeneration [49,50].”
BackgroundMitoenergetic failure in Alzheimer disease
Parihar, M. S., & Brewer, G. J. (2007) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00232.2006 · Cited by 149
“Several lines of evidence link excitotoxicity with the pathogenesis of AD, including 1) oxidative stress and increased intracellular calcium generated in response to A , 2) increases in NMDA receptor activation in response to A , 3) downregulation of glutamate transporters in AD, 4) inhibition of glutamate reuptake by…”
BackgroundInfluentialMolecular and cellular mechanisms of selective vulnerability in neurodegenerative diseases
Kampmann, M. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-024-00806-0 · Cited by 173
“Other currently used drugs target general mechanisms of vulnerability, including excitotoxicity by inhibiting glutamatergic transmission (memantine in AD and riluzole in ALS 210,211 ) or by counteracting reactive oxygen species (edaravone in ALS 212 ).”
Grossberg, G., & Thomas, S. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s6666 · Cited by 151
“This influx of Ca2+ contributes to an alteration of cell function, leading to cell death either through free radicals(8) or through overload of the mitochondria, resulting in free radical formation, caspase activation, and the release of apoptosis-inducing factors.(9) Antagonists to the NMDA vary”
Gu, Z., Nakamura, T., & Lipton, S. A. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8113-9 · Cited by 166
“, NO reaction with the sulfhydryl group of a critical cysteine residue, down-regulates (but does not completely shut off) receptor activity [7, 33].”
InfluentialSelf-citationDong, C.-J., Guo, Y., Agey, P., Wheeler, L. A., & Hare, W. A. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2078 · Cited by 149
Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
Seki, M., & Lipton, S. A. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)01134-5 · Cited by 156
Self-citationDextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
Nguyen, L., Thomas, K. L., Lucke-Wold, B. P., Cavendish, J. Z., Crowe, M. S., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.016 · Cited by 141
“Earlier reviews have summarized the ability of these pharmacological actions to mitigate an array of cellularmechanisms that are common to neurodegenerative conditions including excitotoxicity, calcium dysregulation, oxidative stress, endoplasmic reticulum stress, and mitochondrial dysfunction (Atlante et al., 2001; C…”
BackgroundTarget- and Mechanism-Based Therapeutics for Neurodegenerative Diseases: Strength in Numbers
Trippier, P. C., Labby, K. J., Hawker, D. D., Mataka, J., & Silverman, R. B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3015926 · Cited by 156
Bettini, E., Sava, A., Griffante, C., Carignani, C., Buson, A., Capelli, A. M., Negri, M., Andreetta, F., Senar, S., Guiral, L., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.172544 · Cited by 142
“…and dysfunction of NMDAR activity has been implicated in a variety of neuropathological conditions, including stroke, epilepsy, schizophrenia, depression, Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (Lipton, 2006; Large, 2007; Milnerwood et al., 2010).”
BackgroundAmmonia toxicity and its prevention in inherited defects of the urea cycle
Walker, V. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01054.x · Cited by 142
Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system
Baxter, P. S., Bell, K. F. S., Hasel, P., Kaindl, A. M., Fricker, M., Thomson, D., Cregan, S. P., Gillingwater, T. H., & Hardingham, G. E. (2015) · Nature Communications · doi:10.1038/ncomms7761 · Cited by 139
Nakamura, T., Cieplak, P., Cho, D.-H., Godzik, A., & Lipton, S. A. (2010) · Mitochondrion · doi:10.1016/j.mito.2010.04.007 · Cited by 131
“While many intra- and extracellular molecules may participate in neuronal injury, accumulation of nitrosative stress due to excessive generation of nitric oxide (NO) appears to be a potential factor contributing to neuronal cell damage and death (Lipton, 2006; Lipton and Rosenberg, 1994).”
BackgroundSelf-citationRole of NMDA receptor–dependent activation of SREBP1 in excitotoxic and ischemic neuronal injuries
Taghibiglou, C., Martin, H. G. S., Lai, T. W., Cho, T., Prasad, S. S., Kojic, L., Lu, J., Liu, Y., Lo, E., Zhang, S., et al. (2009) · Nature Medicine · doi:10.1038/nm.2064 · Cited by 144
“Evidence from a number of studies suggests that neuronal excitotoxicity caused by overactivation of NMDARs is a primary neuropathological process contributing to neuronal injury after stroke and brain traum”
BackgroundWenk, G. L., Parsons, C. G., & Danysz, W. (2006) · Behavioural Pharmacology · doi:10.1097/00008877-200609000-00007 · Cited by 128
“The potential mechanisms underlying the neuroprotective effects of memantine have been addressed by others (Chen et al., 1992; Lipton, 2006), who have suggested that memantine blocks NMDA channels in an agonist concentration-dependent manner.”
Background
Metadata
- Authors
- Lipton, S. A.
- Affiliations
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Corresponding author
- Lipton, Stuart A.
- ORCID
- Lipton, Stuart A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-01-20
- Volume
- 5
- Issue
- 2
- Pages
- 160-170
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1981238903
- Cited by
- 909
- References
- 98
- Citations by year
- 2026: 39 · 2025: 31 · 2024: 32 · 2023: 31 · 2022: 40 · 2021: 41 · 2020: 51 · 2019: 42 · 2018: 36 · 2017: 40 · 2016: 48 · 2015: 51 · 2014: 47 · 2013: 48 · 2012: 52
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- memantine, NMDA receptor antagonists, neuroprotection, Alzheimer's disease, dementia, glutamate excitotoxicity, calcium influx, free radicals, adverse drug reactions, clinical trial failure, NMDA receptor overactivation
- MeSH terms
- Animals, Humans, Memantine, Neurotoxins, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.